| Nose | |||||
|---|---|---|---|---|---|
| Nose / Nasal congestion | |||||
| ephedrine hydrochloride | Not approved for prescribing | ||||
| pseudoephedrine hydrochloride | Not approved for prescribing | ||||
| Oral solution | |||||
| Galpseud (Thornton & Ross Ltd) | Not approved for prescribing | ||||
| Sudafed Non-Drowsy Decongestant (McNeil Products Ltd) | Not approved for prescribing | ||||
| xylometazoline hydrochloride | Joint formulary choice | ||||
| Spray | |||||
| Otrivine (Haleon UK Ltd) | Joint formulary choice | ||||
| Sudafed Non-Drowsy Decongestant (McNeil Products Ltd) | Not approved for prescribing | ||||
| Nasal drops | |||||
| Otrivine (Haleon UK Ltd) | Joint formulary choice | ||||
| Nose / Nasal infection | |||||
| betamethasone with neomycin | Not approved for prescribing | ||||
| chlorhexidine with neomycin | Joint formulary choice | ||||
| mupirocin | Joint formulary choice | ||||
| Nasal ointment | |||||
| Bactroban (GlaxoSmithKline UK Ltd) | Joint formulary choice | ||||
| Nose / Nasal inflammation, nasal polyps and rhinitis | |||||
| azelastine hydrochloride | Joint formulary choice | ||||
|
Joint Prescribing Group's decision
October 2019 - the JPG agreed to approved the addition of Rhinolast® (azelastine nasal spray) to the joint formulary for allergic rhinitis. |
|||||
| Spray | |||||
| Rhinolast (Viatris UK Healthcare Ltd) | Joint formulary choice | ||||
| beclometasone dipropionate | Joint formulary choice | ||||
| Spray | |||||
| Beclometasone dipropionate (Non-proprietary) | Joint formulary choice | ||||
| Beconase (GlaxoSmithKline UK Ltd, Omega Pharma Ltd) | Joint formulary choice | ||||
| Nasobec (Teva UK Ltd) | Joint formulary choice | ||||
| betamethasone | Joint formulary choice | ||||
| budesonide | Not approved for prescribing |
NICE TA708 |
|||
| Spray | |||||
| Budesonide (Non-proprietary) | Not approved for prescribing | ||||
| desloratadine | Not approved for prescribing | ||||
| Oral solution | |||||
| Desloratadine (Non-proprietary) | Not approved for prescribing | ||||
| Neoclarityn (Organon Pharma (UK) Ltd) | Not approved for prescribing | ||||
| dupilumab | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA534 NICE TA751 |
|||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Solution for injection | |||||
| Dupixent (Sanofi) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| fexofenadine hydrochloride | Joint formulary choice | ||||
| fluticasone | Joint formulary choice | ||||
| Spray | |||||
| Fluticasone (Non-proprietary) | Joint formulary choice | ||||
| Avamys (GlaxoSmithKline UK Ltd) | Specialist knowledge/initiation | ||||
| Flixonase (GlaxoSmithKline UK Ltd, Haleon UK Ltd) | Joint formulary choice | ||||
| Nasofan (Teva UK Ltd) | Joint formulary choice | ||||
| fluticasone with azelastine | Joint formulary choice | ||||
| Spray | |||||
| Dymista (Viatris UK Healthcare Ltd) | Joint formulary choice | ||||
| ipratropium bromide | Not approved for prescribing | ||||
| Spray | |||||
| Rinatec (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||
| ketotifen | Not approved for prescribing | ||||
| Oral solution | |||||
| Zaditen (CD Pharma Srl) | Not approved for prescribing | ||||
| Eye drops | |||||
| Zaditen (Thea Pharmaceuticals Ltd) | Not approved for prescribing | ||||
| mometasone furoate | Joint formulary choice | ||||
| Spray | |||||
| Mometasone furoate (Non-proprietary) | Joint formulary choice | ||||
| Nasonex (Organon Pharma (UK) Ltd) | Joint formulary choice | ||||
| rupatadine | Not approved for prescribing | ||||
| triamcinolone acetonide | Not approved for prescribing | ||||
| Suspension for injection | |||||
| Kenalog (Bristol-Myers Squibb Pharmaceuticals Ltd) | Not approved for prescribing | ||||
| Spray | |||||
| Nasacort (Sanofi Consumer Healthcare) | Not approved for prescribing | ||||